Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

However, it's definitely a good sign that Sciele paid 2 a share for its equity stake.

I think another good sign is that PLE is meeting with analysts once its results are published. Clearly the co thinks it can provoke a rerating.

soul traders -don't forget the other PSD502 deals for woundpain and PE for other world areas have yet to come. Next week they will probably give actual figures to the deal. I like the deal because Plethoras other major products fit well into Sciele's organisational portfolio too -The OAB products are even massive.

And they have a good deal with MLR

they have
signed an exclusive license agreement for the marketing of PSD502 for premature
ejaculation (PE) in the United States together with an agreement for Sciele to
purchase a $7 million equity stake in Plethora.

This is interesing because they state that they have signed an exclusive license agreement together with the stake -so that means the agreement terms will be announced I guess next week on 30th May ref royalty payments etc -just my conclusion!!!

I have my doubts as to whether we'll learnt the terms of the deal. Why did PLE not announce them today?

soul -its clear that we haven't had the whole information -reason I guess is that the results are on 30th May so it would make sense to blend everything in together with all other financial info. But the wording in todays news is clear that more info will be given. The clue is the word "together" in the news. Together is the Sciele purchase of shares but the deal agreement info should follow -some peeps haven't cottoned on yet I guess.
It'll get to 2 anyway I guess based on the purchase info.

MM's have woken up -they are buying now -ready for next week and beyond!

Up again today: PLE Bid: 174p Offer: 181p Change: 2.5

Dumped this and bought HAWK. Have spent too long waiting for PLE to do something spectacular on the back of the PE product deal, which it hasn't done. Will watch and see how increased revenues affect this in the future, but am on the sidelines for now.

Good luck to holders.

does anyone understand why PLE has moved to FTSE AIM 50??

watch PLE watch MLR

watch PLE - based on??

The fact that a 100% of males, real males that is, not whimpish poofters, want a hard on and only about 75%(BMJ) are able to.

It's about half the sp when you posted David10B - what can you suggest is the reason? . . . . I agree that this appears to be a product men would give their rt arm for (almost), yet now it's at an all-time low - although not that low I'm tempted to buy for "recovery". This slide looks like carelessness - eyes-off-balls etc.

I note that a PhIII-trial is to start for premature ejaculation - something like the hullabaloo over the SP a few years ago....Maybe it's the "Jam tomorrow" problem over again...

EDIT(17Nov08)-16p/19p . . . As I read it, the erectile product is a vacuum-device, whereas I was believing this company was offering a drug-pased product. Doh! - this was 1 only last November!
- Anyone? -

LONDON (ShareCast) - Plethora Solutions (LSE: PLE.L - news) is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler.

Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two phase III trials and is currently awaiting European approval. This approval is expected late in the third quarter or early fourth quarter of 2013.

Importantly, it announced at its interims on December 28th that talks "had commenced with multiple parties to identify a commercial partner to bring PDS502 product to market.

Alexandre believes the stock is "grossly undervalued" and has placed a price target of 15.7p on it, 214% upside on its current 5p price.

Now, as house broker you might perhaps expect him to be keen on the stock but he's positively enthusiastic, while noting that its closing cash balance at the interims was only £0.2m, which means: "We estimate that the company will need to secure further financing."

He's confident that the next 12 months will see the transformation of the company, with the signing of a deal probably before EU approval, as any partner would have to factor in a ramp-up period prior to the product's launch. With that deal would come some sorely needed funds.

With an estimated 30m European men as potential targets for this treatment it may be a compelling investment case.

Alexandre thinks it is: "We believe that PSD502 has the potential to 'go mass market'. Should this transpire, our estimates of the treatment's market potential would be significantly increased. That said, even if the treatment achieves a fraction of this market penetration, Plethora's business would be substantially transformed."

For those of a cautious disposition, who like to invest in well-funded companies, it might be worth holding off until any deal is announced. Yet, the fact that billionaire Jim Mellon, a non-executive director of the company, has been funding the company in return for shares, ought to offer some reassurance for those prepared to gamble on this biotech play.

:-))

Tipped in this weeks share mag. Analysts at Daniel Stewart carry a 15.7p target price in the view strong sales growth and expected launch of the new drug could ''substantially'' transform the business. Management expects European approval for PSD502 in the second half of 2013. The drug has completed two phase III trials and could be launched in the first half of 2014.

I'm in as of earler today...anyone else still in ? any views?

SP up a bit this morning... all looking good so far!